PRESS RELEASE

Q1 2025 — Press release

Q1 2025PDF · 19 pages1.4 MB
For immediate release

-- 1 of 19 --



-- 2 of 19 --

2.0% – 3.0% / 2.5% 2.0% – 3.0% / 2.5%
$91.6B – $92.4B / $92.0B
3.3% – 4.3% / 3.8%
$90.9B – $91.7B / $91.3B
2.5% – 3.5% / 3.0%
$91.0B – $91.8B / $91.4B
2.6% – 3.6% / 3.1%
$89.2B – $90.0B / $89.6B
0.5% – 1.5% / 1.0%
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
$10.75 – $10.95 / $10.85
7.7% – 9.7% / 8.7%
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%

-- 3 of 19 --



-- 4 of 19 --



-- 5 of 19 --



-- 6 of 19 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2025 2024 Total Operations Currency
Sales to customers by
segment of business
Innovative Medicine
U.S. 8,092	$ 7,612 6.3 % 6.3 -
International 5,781 5,950 (2.9) 1.5 (4.4)
13,873 13,562 2.3 4.2 (1.9)
MedTech
U.S. 4,213 4,008 5.1 5.1 -
International 3,807 3,813 (0.2) 3.0 (3.2)
8,020 7,821 2.5 4.1 (1.6)
U.S. 12,305 11,620 5.9 5.9 -
International 9,588 9,763 (1.8) 2.1 (3.9)
Worldwide 21,893	$ 21,383 2.4 % 4.2 (1.8)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 7 of 19 --

Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
2025 2024 Total Operations Currency
Sales to customers by
geographic area
U.S. 12,305	$ 11,620 5.9 % 5.9 -
Europe 5,110 5,163 (1.0) 2.2 (3.2)
Western Hemisphere excluding U.S. 1,167 1,194 (2.3) 9.2 (11.5)
Asia-Pacific, Africa 3,311 3,406 (2.8) (0.6) (2.2)
International 9,588 9,763 (1.8) 2.1 (3.9)
Worldwide 21,893	$ 21,383 2.4 % 4.2 (1.8)
Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.
FIRST QUARTER
Percent Change

-- 8 of 19 --

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share Figures)
Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers 21,893	$ 100.0 21,383	$ 100.0 2.4
Cost of products sold 7,357 33.6 6,511 30.4 13.0
Gross Profit 14,536 66.4 14,872 69.6 (2.3)
Selling, marketing and administrative expenses 5,112 23.3 5,257 24.6 (2.8)
Research and development expense 3,225 14.7 3,542 16.6 (8.9)
Interest (income) expense, net (128) (0.6) (209) (1.0)
Other (income) expense, net (7,321) (33.4) 2,404 11.2
Restructuring 17 0.1 164 0.8
Earnings before provision for taxes on income 13,631 62.3 3,714 17.4 267.0
Provision for taxes on income 2,632 12.1 459 2.2 473.4
Net earnings 10,999	$ 50.2 3,255	$ 15.2 237.9
Net earnings per share (Diluted) 4.54	$ 1.34	$ 238.8
Average shares outstanding (Diluted) 2,423.8 2,430.1
Effective tax rate 19.3 % 12.4 %
Adjusted earnings before provision for taxes and net earnings (1)
Earnings before provision for taxes on income 8,011	$ 36.6 7,877	$ 36.8 1.7
Net earnings 6,706	$ 30.6 6,580	$ 30.8 1.9
Net earnings per share (Diluted) 2.77	$ 2.71	$ 2.2
Effective tax rate 16.3 % 16.5 %
(1) See Reconciliation of Non-GAAP Financial Measures.
FIRST QUARTER
2025 2024

-- 9 of 19 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures
(Dollars in Millions Except Per Share Data) 2025 2024
Net Earnings, after tax- as reported $10,999 $3,255
Pre-tax Adjustments
Litigation related (6,966) 2,726
Intangible Asset Amortization expense 1,120 1,078
Restructuring related 1 55 171
Acquisition, integration and divestiture related 132 148
(Gains)/losses on securities 39 (20)
Medical Device Regulation - 51
COVID-19 Vaccine related costs - 9
Tax Adjustments
Tax impact on special item adjustments 2 1,315 (856)
Tax legislation and other tax related 12 18
Adjusted Net Earnings, after tax $6,706 $6,580
Average shares outstanding (Diluted) 2,423.8 2,430.1
Adjusted net earnings per share (Diluted) $2.77 $2.71
Operational adjusted net earnings per share (Diluted) $2.81
Notes:
1
2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in
arriving at adjusted earnings.
First Quarter
In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to
focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The
R&D program exits are primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine
program, hepatitis and HIV development. The restructuring expenses of $144 million in the fiscal first quarter of 2024 include the termination of
partnered and non-partnered program costs and asset impairments. This program was completed in Q4 2024.
In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by
exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $55 million in the fiscal first quarter of
2025 and $27 million in the fiscal first quarter of 2024 primarily includes costs related to market and product exits.

-- 10 of 19 --

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measure
Innovative Medicine MedTech Total
WW As Reported 2.3% 2.5% 2.4%
U.S. 6.3% 5.1% 5.9%
International (2.9)% (0.2)% (1.8)%
WW Currency (1.9) (1.6) (1.8)
U.S. - - -
International (4.4) (3.2) (3.9)
WW Operational 4.2% 4.1% 4.2%
U.S. 6.3% 5.1% 5.9%
International 1.5% 3.0% 2.1%
Shockwave (3.3) (1.2)
U.S. (5.1) (1.8)
International (1.4) (0.5)
All Other Acquisitions and Divestitures (A&D) 0.2 0.5 0.3
U.S. 0.0 0.9 0.3
International 0.4 0.2 0.3
WW Adjusted Operational Ex A&D 4.4% 1.3% 3.3%
U.S. 6.3% 0.9% 4.4%
International 1.9% 1.8% 1.9%
Adjusted Operational Sales Growth
FIRST QUARTER 2025 ACTUAL vs. 2024 ACTUAL
Segments
Note: Percentages are based on actual, non-rounded figures and may not sum

-- 11 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
INNOVATIVE MEDICINE SEGMENT (2) 2025 2024 Reported Operational (1) Currency
ONCOLOGY
US 3,013	$ 2,383 26.4% 26.4% -
Intl 2,664 2,430 9.6% 14.4% -4.8%
WW 5,678 4,814 17.9% 20.4% -2.5%
CARVYKTI
US 318 140 * * -
Intl 51 16 * * *
WW 369 157 * * *
DARZALEX
US 1,829 1,464 24.9% 24.9% -
Intl 1,409 1,228 14.7% 19.8% -5.1%
WW 3,237 2,692 20.3% 22.5% -2.2%
ERLEADA
US 292 285 2.5% 2.5% -
Intl 479 404 18.5% 23.1% -4.6%
WW 771 689 11.9% 14.6% -2.7%
IMBRUVICA
US 235 265 -11.5% -11.5% -
Intl 474 518 -8.5% -4.2% -4.3%
WW 709 784 -9.5% -6.7% -2.8%
RYBREVANT / LAZCLUZE (3)
US 113 36 * * -
Intl 28 11 * * *
WW 141 47 * * *
TALVEY (3)
US 68 50 35.2% 35.2% -
Intl 18 8 * * *
WW 86 58 48.4% 50.2% -1.8%
TECVAYLI
US 105 101 4.9% 4.9% -
Intl 46 33 38.8% 45.9% -7.1%
WW 151 133 13.3% 15.0% -1.7%
ZYTIGA / abiraterone acetate
US 7 9 -24.3% -24.3% -
Intl 118 172 -31.3% -28.5% -2.8%
WW 125 181 -30.9% -28.3% -2.6%
OTHER ONCOLOGY (3)
US 47 33 42.9% 42.9% -
Intl 42 41 4.6% 10.1% -5.5%
WW 89 73 21.7% 24.7% -3.0%
See footnotes at end of schedule
% Change

-- 12 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2025 2024 Reported Operational (1) Currency
IMMUNOLOGY
US 2,196 2,453 -10.5% -10.5% -
Intl 1,510 1,794 -15.8% -11.5% -4.3%
WW 3,707 4,247 -12.7% -10.9% -1.8%
REMICADE
US 314 266 18.1% 18.1% -
US Exports (4) 10 27 -64.2% -64.2% -
Intl 143 141 1.3% 6.8% -5.5%
WW 467 434 7.5% 9.3% -1.8%
SIMPONI / SIMPONI ARIA
US 292 254 14.8% 14.8% -
Intl 366 299 22.4% 29.7% -7.3%
WW 659 554 18.9% 22.9% -4.0%
STELARA
US 981 1,396 -29.8% -29.8% -
Intl 644 1,055 -38.9% -35.8% -3.1%
WW 1,625 2,451 -33.7% -32.3% -1.4%
TREMFYA
US 599 509 17.6% 17.6% -
Intl 356 299 19.2% 24.4% -5.2%
WW 956 808 18.2% 20.1% -1.9%
OTHER IMMUNOLOGY
US 1 0 * * -
Intl 0 0 - - -
WW 1 0 * * -
NEUROSCIENCE
US 968 1,054 -8.1% -8.1% -
Intl 679 749 -9.3% -5.5% -3.8%
WW 1,647 1,803 -8.6% -7.0% -1.6%
CONCERTA / Methylphenidate
US 38 41 -7.4% -7.4% -
Intl 110 136 -18.9% -15.2% -3.7%
WW 148 177 -16.3% -13.4% -2.9%
INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA
US 625 765 -18.2% -18.2% -
Intl 277 292 -4.9% -1.1% -3.8%
WW 903 1,056 -14.5% -13.5% -1.0%
SPRAVATO
US 276 191 45.0% 45.0% -
Intl 43 34 25.0% 31.7% -6.7%
WW 320 225 41.9% 42.9% -1.0%
OTHER NEUROSCIENCE
US 28 58 -50.6% -50.6% -
Intl 248 287 -13.4% -9.8% -3.6%
WW 277 345 -19.6% -16.7% -2.9%
See footnotes at end of schedule
% Change

-- 13 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2025 2024 Reported Operational (1) Currency
PULMONARY HYPERTENSION
US 744 766 -2.9% -2.9% -
Intl 281 283 -0.6% 3.2% -3.8%
WW 1,025 1,049 -2.3% -1.2% -1.1%
OPSUMIT / OPSYNVI (3)
US 363 356 2.1% 2.1% -
Intl 159 169 -6.0% -2.5% -3.5%
WW 522 524 -0.5% 0.6% -1.1%
UPTRAVI
US 365 392 -6.9% -6.9% -
Intl 86 76 13.4% 17.5% -4.1%
WW 451 468 -3.6% -2.9% -0.7%
OTHER PULMONARY HYPERTENSION(3)
US 15 18 -12.7% -12.7% -
Intl 37 39 -4.6% -0.3% -4.3%
WW 52 56 -7.2% -4.3% -2.9%
INFECTIOUS DISEASES
US 315 324 -2.8% -2.8% -
Intl 487 497 -1.9% 1.9% -3.8%
WW 802 821 -2.2% 0.1% -2.3%
EDURANT / rilpivirine
US 8 8 -1.3% -1.3% -
Intl 350 315 11.0% 14.7% -3.7%
WW 358 323 10.7% 14.3% -3.6%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA
US 305 314 -2.9% -2.9% -
Intl 98 104 -6.2% -0.6% -5.6%
WW 403 418 -3.7% -2.3% -1.4%
OTHER INFECTIOUS DISEASES (3)
US 2 2 7.7% 7.7% -
Intl 39 77 -48.8% -47.0% -1.8%
WW 41 78 -47.6% -45.9% -1.7%
CARDIOVASCULAR / METABOLISM / OTHER
US 855 631 35.4% 35.4% -
Intl 158 197 -19.7% -15.3% -4.4%
WW 1,013 829 22.3% 23.4% -1.1%
XARELTO
US 690 518 33.3% 33.3% -
Intl - - - - -
WW 690 518 33.3% 33.3% -
OTHER
US 165 114 45.0% 45.0% -
Intl 158 197 -19.7% -15.3% -4.4%
WW 323 311 3.9% 6.7% -2.8%
TOTAL INNOVATIVE MEDICINE
US 8,092 7,612 6.3% 6.3% -
Intl 5,781 5,950 -2.9% 1.5% -4.4%
WW 13,873	$ 13,562 2.3% 4.2% -1.9%
See footnotes at end of schedule
% Change

-- 14 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
MEDTECH SEGMENT (2) 2025 2024 Reported Operational (1) Currency
CARDIOVASCULAR
US 1,261	$ 1,025 23.0% 23.0% -
Intl 842 781 7.8% 10.7% -2.9%
WW 2,103 1,806 16.4% 17.7% -1.3%
ELECTROPHYSIOLOGY
US 684 692 -1.1% -1.1% -
Intl 638 652 -2.0% 0.7% -2.7%
WW 1,323 1,344 -1.6% -0.2% -1.4%
ABIOMED
US 339 303 11.9% 11.9% -
Intl 81 67 19.7% 23.6% -3.9%
WW 420 371 13.3% 14.0% -0.7%
SHOCKWAVE (5)
US 206 - * * -
Intl 52 - * * -
WW 258 - * * -
OTHER CARDIOVASCULAR
US 32 30 7.1% 7.1% -
Intl 72 62 15.1% 17.4% -2.3%
WW 103 92 12.5% 14.1% -1.6%
ORTHOPAEDICS
US 1,384 1,448 -4.4% -4.4% -
Intl 857 892 -3.9% -0.9% -3.0%
WW 2,241 2,340 -4.2% -3.1% -1.1%
HIPS
US 263 270 -2.5% -2.5% -
Intl 146 152 -4.0% -0.8% -3.2%
WW 409 422 -3.1% -1.9% -1.2%
KNEES
US 231 242 -4.3% -4.3% -
Intl 158 160 -1.0% 2.1% -3.1%
WW 389 401 -3.0% -1.7% -1.3%
TRAUMA
US 502 504 -0.5% -0.5% -
Intl 270 261 3.7% 7.2% -3.5%
WW 772 765 0.9% 2.1% -1.2%
SPINE, SPORTS & OTHER
US 388 432 -10.2% -10.2% -
Intl 283 320 -11.6% -8.9% -2.7%
WW 671 752 -10.8% -9.7% -1.1%
See footnotes at end of schedule
% Change

-- 15 of 19 --

REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
2025 2024 Reported Operational (1) Currency
SURGERY
US 1,002 987 1.5% 1.5% -
Intl 1,394 1,429 -2.5% 0.8% -3.3%
WW 2,396 2,416 -0.8% 1.1% -1.9%
ADVANCED
US 457 446 2.7% 2.7% -
Intl 616 641 -4.0% -1.0% -3.0%
WW 1,073 1,087 -1.2% 0.5% -1.7%
GENERAL
US 544 542 0.5% 0.5% -
Intl 778 788 -1.2% 2.3% -3.5%
WW 1,323 1,330 -0.5% 1.6% -2.1%
VISION
US 566 547 3.4% 3.4% -
Intl 713 710 0.4% 3.9% -3.5%
WW 1,279 1,258 1.7% 3.7% -2.0%
CONTACT LENSES / OTHER
US 452 438 3.1% 3.1% -
Intl 467 472 -1.1% 2.4% -3.5%
WW 919 910 1.0% 2.7% -1.7%
SURGICAL
US 114 110 4.3% 4.3% -
Intl 246 238 3.4% 7.1% -3.7%
WW 361 348 3.7% 6.2% -2.5%
TOTAL MEDTECH
US 4,213 4,008 5.1% 5.1% -
Intl 3,807 3,813 -0.2% 3.0% -3.2%
WW 8,020	$ 7,821 2.5% 4.1% -1.6%
* Percentage greater than 100% or not meaningful
(1) Operational growth excludes the effect of translational currency
(2) Unaudited
(3) See Supplemental Sales Information Schedule
(4) Reported as U.S. sales
(5) Acquired on May 31, 2024
Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
therefore, may not recalculate precisely
% Change

-- 16 of 19 --

2023 2024
Full Year Q1 Q2 Q3 Q4 Full Year
INNOVATIVE MEDICINE SEGMENT
ONCOLOGY
RYBREVANT / LAZCLUZE
US 66 36 52 68 101 257
INTL 27 11 17 21 21 70
WW 93 47 69 89 122 327
TALVEY
US 56 50 59 64 68 241
INTL 7 8 9 12 17 46
WW 63 58 69 75 85 287
OTHER ONCOLOGY
US 93 33 37 36 39 145
INTL 235 41 45 50 36 172
WW 328 73 83 86 75 317
PULMONARY HYPERTENSION
OPSUMIT / OPSYNVI
US 1,292 356 376 417 408 1,557
INTL 681 169 171 166 162 668
WW 1,973 524 548 583 570 2,225
OTHER PULMONARY HYPERTENSION
US 79 18 17 21 19 75
INTL 182 39 49 39 38 165
WW 260 56 67 60 57 240
INFECTIOUS DISEASES
OTHER INFECTIOUS DISEASES (1)
US 19 2 5 3 1 11
INTL 1,395 77 227 54 43 401
WW 1,414 78 233 56 45 412
(1) Other Infectious Diseases is inclusive of COVID-19 Vaccine sales, which were previously disclosed separately
Note: Columns and rows within tables may not add due to rounding
2024
Supplemental Sales Information (Unaudited)
(Dollars in Millions)

-- 17 of 19 --

Innovative Medicine
First Quarter
March 30,
2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30,
2025
Non-GAAP
Cost of products sold 4,020	$ (649) 3,371
Selling, marketing and admin expenses 2,261 2,261
Research and development expense 2,548 2,548
Other segment items (166) - - - (20) (18) - (204)
Adjusted Income Before Tax by Segment 5,210 649 - - 20 18 - 5,897
MedTech
First Quarter
March 30,
2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30,
2025
Non-GAAP
Cost of products sold 3,326	$ (471) (8) (52) 2,795
Selling, marketing and admin expenses 2,656 2,656
Research and development expense 677 (6) 671
Other segment items (60) - - (47) (54) (21) - (182)
Adjusted Income Before Tax by Segment 1,421 471 - 55 112 21 - 2,080
Expenses not allocated to segments
First Quarter
March 30,
2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30,
2025
Non-GAAP
Cost of products sold 11	$ 11
Selling, marketing and admin expenses 195 195
Research and development expense -
Other segment items (7,206) - 6,966 - - - - (240)
Adjusted Income Before Tax by Segment 7,000 - (6,966) - - - - 34
Johnson & Johnson Consolidated
First Quarter
March 30,
2025
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Tax legislation
and other tax
related
First Quarter
March 30,
2025
Non-GAAP
Cost of products sold 7,357	$ (1,120) (8) (52) - 6,177
Selling, marketing and admin expenses 5,112 5,112
Research and development expense 3,225 (6) 3,219
Other (Income) / Expense (7,321) - 6,966 (30) (74) (39) (498)
In-process research and development impairments - -
Interest (Income)/Expense (128) (128)
Restructuring 17 (17) -
Adjusted Income Before Tax 13,631 1,120 (6,966) 55 132 39 - 8,011
Provision for taxes on income 2,632 188 (1,553) 11 30 9 (12) 1,305
Net Earnings 10,999 932 (5,413) 44 102 30 12 6,706
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Year to Date

-- 18 of 19 --

Innovative Medicine
First Quarter
March 31, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
First Quarter
March 31, 2024
Non-GAAP
Cost of products sold 3,370	$ (698) (2) 2,670
Selling, marketing and admin expenses 2,438 2,438
Research and development expense 2,896 (7) 2,889
Other segment items (111) (144) (47) 55 (247)
Adjusted Income Before Tax by Segment 4,969 698 - 144 47 (55) - 9 - 5,812
MedTech
First Quarter
March 31, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
First Quarter
March 31, 2024
Non-GAAP
Cost of products sold 3,120	$ (380) (7) (20) 2,713
Selling, marketing and admin expenses 2,582 (4) 2,578
Research and development expense 646 (18) (27) 601
Other segment items (47) (20) (43) (22) (132)
Adjusted Income Before Tax by Segment 1,520 380 - 27 61 22 51 - - 2,061
Expenses not allocated to segments
First Quarter
March 31, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
First Quarter
March 31, 2024
Non-GAAP
Cost of products sold 21	$ 21
Selling, marketing and admin expenses 237 237
Research and development expense - -
Other segment items 2,517 (2,726) (40) (13) (262)
Adjusted Income Before Tax by Segment (2,775) - 2,726 - 40 13 - - - 4
Johnson & Johnson Consolidated
First Quarter
March 31, 2024
GAAP
Intangible asset
amortization
Litigation
related
Restructuring
related
Acquisition,
integration and
divestiture related
(Loss)/gain on
securities
Medical Device
Regulation
COVID-19
Vaccine Related
Costs
Tax legislation
and other tax
related
First Quarter
March 31, 2024
Non-GAAP
Cost of products sold 6,511	$ (1,078) (7) (20) (2) 5,404
Selling, marketing and admin expenses 5,257 (4) 5,253
Research and development expense 3,542 (18) (27) (7) 3,490
Other (Income) / Expense 2,404 (2,726) (130) 20 (432)
In-process research and development impairments - -
Interest (Income)/Expense (209) (209)
Restructuring 164 (164) -
Adjusted Income Before Tax 3,714 1,078 2,726 171 148 (20) 51 9 - 7,877
Provision for taxes on income 459 148 627 39 38 (7) 9 2 (18) 1,297
Net Earnings 3,255 930 2,099 132 110 (13) 42 7 18 6,580
Johnson & Johnson and Subsidiaries
GAAP to Non-GAAP Reconciliation
$ in Millions
Year to Date

-- 19 of 19 --